Targeting a specific gene modification to treat Alzheimer's disease and related dementias
Targeting Histone K4 Methylation for Treatment of Alzheimer's Disease and Related Dementia
['FUNDING_R01'] · STATE UNIVERSITY OF NEW YORK AT BUFFALO · NIH-10599193
This study is looking at how certain changes in brain proteins might affect Alzheimer's and frontotemporal dementia, with the hope of finding new ways to help improve memory and thinking for people living with these conditions.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NEW YORK AT BUFFALO (nih funded) |
| Locations | 1 site (AMHERST, UNITED STATES) |
| Trial ID | NIH-10599193 on ClinicalTrials.gov |
What this research studies
This research investigates the role of histone K4 methylation in the development and treatment of Alzheimer's disease and frontotemporal dementia. By analyzing brain tissues from patients and using animal models, the study aims to understand how changes in gene expression contribute to these neurodegenerative conditions. The researchers will employ various techniques, including molecular and behavioral assessments, to explore the potential of targeting specific enzymes that modify histone proteins to improve cognitive function and memory. This approach could lead to new therapeutic strategies for patients suffering from these debilitating diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or frontotemporal dementia, particularly those experiencing cognitive decline.
Not a fit: Patients with other forms of dementia not related to Alzheimer's or frontotemporal dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that improve memory and cognitive function in patients with Alzheimer's disease and related dementias.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic modifications for neurodegenerative diseases, indicating potential for success in this novel approach.
Where this research is happening
AMHERST, UNITED STATES
- STATE UNIVERSITY OF NEW YORK AT BUFFALO — AMHERST, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YAN, ZHEN — STATE UNIVERSITY OF NEW YORK AT BUFFALO
- Study coordinator: YAN, ZHEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease